BriaCell Therapeutics' Phase 3 Breast Cancer Treatment Trial Gets Fifth DSMB Recommendation to Continue

MT Newswires Live

Yesterday

BriaCell Therapeutics (BCTX) said Tuesday an independent data safety monitoring board has recommended for the fifth time continuation of a phase 3 study of its Bria-IMT plus an immune checkpoint inhibitor to treat metastatic breast cancer patients after reviewing safety data.

The company said the board, which neets quarterly in accordance with the study protocol, reported no safety concerns and recommended the study continue without modifications.

The trial is being conducted under a US Food and Drug Administration 'Fast Track' designation, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612452720"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612452720\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612452720?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-17 21:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612452720","market":"us","top_or_hot":-1,"title":"BriaCell Therapeutics' Phase 3 Breast Cancer Treatment Trial Gets Fifth DSMB Recommendation to Continue","media":"MT Newswires Live","content":"<html><body><p> BriaCell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (BCTX) said Tuesday an independent data safety monitoring board has recommended for the fifth time continuation of a phase 3 study of its Bria-IMT plus an immune checkpoint inhibitor to treat metastatic breast cancer patients after reviewing safety data.</p><p>The company said the board, which neets quarterly in accordance with the study protocol, reported no safety concerns and recommended the study continue without modifications.</p><p>The trial is being conducted under a US Food and Drug Administration '<a href=\"https://laohu8.com/S/FTRK\">Fast Track</a>' designation, the company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BriaCell Therapeutics' Phase 3 Breast Cancer Treatment Trial Gets Fifth DSMB Recommendation to Continue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBriaCell Therapeutics' Phase 3 Breast Cancer Treatment Trial Gets Fifth DSMB Recommendation to Continue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-17 21:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BriaCell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (BCTX) said Tuesday an independent data safety monitoring board has recommended for the fifth time continuation of a phase 3 study of its Bria-IMT plus an immune checkpoint inhibitor to treat metastatic breast cancer patients after reviewing safety data.</p><p>The company said the board, which neets quarterly in accordance with the study protocol, reported no safety concerns and recommended the study continue without modifications.</p><p>The trial is being conducted under a US Food and Drug Administration '<a href=\"https://laohu8.com/S/FTRK\">Fast Track</a>' designation, the company said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCTX","symbol_name":"BriaCell Therapeutics Corp.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2612452720","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612452720","pubTimestamp":1771334096,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BriaCell Therapeutics  said Tuesday an independent data safety monitoring board has recommended for the fifth time continuation of a phase 3 study of its Bria-IMT plus an immune checkpoint inhibitor to treat metastatic breast cancer patients after reviewing safety data.The company said the board, which neets quarterly in accordance with the study protocol, reported no safety concerns and recommended the study continue without modifications.The trial is being conducted under a US Food and Drug Administration 'Fast Track' designation, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCTX":"BriaCell Therapeutics Corp.","BK4139":"生物科技"},"translate_title":"BriaCell Therapeutics的3期乳腺癌治疗试验获得第五次DSMB建议继续进行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCTX":1.5},"content_text":"BriaCell Therapeutics (BCTX) said Tuesday an independent data safety monitoring board has recommended for the fifth time continuation of a phase 3 study of its Bria-IMT plus an immune checkpoint inhibitor to treat metastatic breast cancer patients after reviewing safety data.The company said the board, which neets quarterly in accordance with the study protocol, reported no safety concerns and recommended the study continue without modifications.The trial is being conducted under a US Food and Drug Administration 'Fast Track' designation, the company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}